Avadel Jumps On $2.1 Billion Takeover Deal. But Buyer, Alkermes, Dives.Investors Business Daily • 10/22/25
AVDL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avadel Pharmaceuticals plc Is Fair to ShareholdersBusiness Wire • 10/22/25
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 10/13/25
Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research FundingGlobeNewsWire • 09/16/25
Avadel Pharmaceuticals Plc (AVDL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/09/25
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025GlobeNewsWire • 09/05/25
Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma LtdGlobeNewsWire • 09/03/25
Does Avadel (AVDL) Have the Potential to Rally 27.95% as Wall Street Analysts Expect?Zacks Investment Research • 08/27/25
Wall Street Analysts Predict a 37.25% Upside in Avadel (AVDL): Here's What You Should KnowZacks Investment Research • 08/11/25
Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue GuidanceGlobeNewsWire • 08/07/25
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7GlobeNewsWire • 07/31/25
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act LitigationGlobeNewsWire • 06/30/25
ASL Strategic Value Fund targets Avadel board over Lumryz drug mismanagement, WSJ reportsReuters • 06/30/25
An investor in the narcolepsy drugmaker Avadel Pharmaceuticals plans to call for shareholders to vote out the company's entire board of directors, ratcheting up pressureWSJ • 06/30/25
Wall Street Analysts See an 81.61% Upside in Avadel (AVDL): Can the Stock Really Move This High?Zacks Investment Research • 06/16/25